(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The "Global Radiodermatitis Market (2023-2028) by Product, Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The worldwide Radiodermatitis market is poised for substantial expansion, projected to grow from USD 524.76 million in 2023 to USD 641.54 million by 2028, indicating a Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period.
Market Overview
Radiodermatitis, a skin condition caused by ionizing radiation used in cancer therapies like radiotherapy, leads to inflammation, redness, itching, and even blisters or ulcers. Proper skincare during therapy is essential for symptom relief and enhancing patients' quality of life.
Market Dynamics
The aging population is a major driver of radiodermatitis treatments. The rising incidence of cancer with age increases the demand for treatment, particularly as older individuals may have more vulnerable skin. Additionally, the increasing prevalence of cancer cases and the growing use of radiotherapy contribute to market growth.
Market Segmentations
The market is segmented by product (Topical, Oral Drugs, Dressings), distribution channel (Hospital Pharmacies, Retail Pharmacy, Online Pharmacy), and geography (Americas, Europe, Middle-East & Africa, Asia-Pacific). Topical products, such as corticosteroids and creams, hold a significant market share, and Hospital Pharmacies play a crucial role in distribution.
Recent Developments
Recent developments include Helsinn's financing agreement with Oberland Capital and Perrigo's completion of the acquisition of HRA Pharma.
Conclusion
The global Radiodermatitis market is set for growth driven by factors like the aging population, rising cancer prevalence, and the increased use of radiotherapy. Although challenges exist, opportunities arise from the demand for reduced radiation therapy side effects, creating a market for innovative products and solutions.
Companies Mentioned
Acelity LP Inc. AcelRx Pharmaceuticals, Inc. Advancis Medical Alliqua BioMedical, Inc. Bausch Health Companies Inc. Bayer Ag BMG Pharma S.p.A. Convatec Group PLC Derma Sciences Inc. GlaxoSmithKline PLC Helsinn Healthcare Medline Industries, Inc. Molnlycke Health Care AB Mylan N.V. Perrigo Company plc PuriCore Inc. RDT Pacific Smith & Nephew PLC Stratpharma Ag The 3M Company
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 206 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $524.76 Million |
| Forecasted Market Value (USD) by 2028 | $641.54 Million |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarketsis the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Global Radiodermatitis Market
Global Radiodermatitis Market Global Radiodermatitis Market Tags Dermatological Drugs Radiodermatitis Market Radiodermatitis Treatment Radiodermatitis Drug id="media-image-1" loading="lazy" src=' />
MENAFN31082023004107003653ID1106990975
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.